AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00666796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ethanol
Description: Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
Study NCT00666796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
Study NCT00666796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
Study NCT00666796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
Study NCT00666796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
Study NCT00666796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ethanol
Description: Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
Study NCT01374711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
Study NCT01374711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IFN-Y
Description: IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
Study NCT01374711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E.coli endotoxin
Description: 2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
Study NCT01374711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E.coli endotoxin
Description: 2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
Study NCT03911219 — intervention group
Intervention type: OTHER
Intervention: eHealth system support for symptom management via CANKADO
Description: Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.
Study NCT04343833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dental implants
Description: At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
Study NCT04178863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CATS Tonometer
Description: latanoprost vs. timolol
Study NCT04178863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: latanoprost IOP reduction
Study NCT02262221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scheduled radiologic evaluations
Description: Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
Study NCT00485342 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Peg-interferon alpha 2a and ribavin
Description: Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
Study NCT00485342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin with adaptation dose
Description: Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
Study NCT04882605 — intervention group
Intervention type: GENETIC
Intervention: MHC typing
Description: Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.
Study NCT04882605 — intervention group
Intervention type: GENETIC
Intervention: KIR typing
Description: Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.
Study NCT00559936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Avastin 1%
Description: Avastin (bevacizumab) 1%
Study NCT01827280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
Study NCT00679055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-0736
Description: MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
Study NCT00679055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo (unspecified)
Description: Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
Study NCT04882605 — intervention group
Intervention type: GENETIC
Intervention: Assessment of KIR-based prediction scores
Description: Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores
Study NCT03580148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone
Description: Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
Study NCT03580148 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspirate
Description: Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
Study NCT02012777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
Study NCT03622749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Non-Invasive neuromodulation
Study NCT01367119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
Study NCT01367119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methohexital
Description: Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
Study NCT04512625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Desensitizers
Description: The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.
Study NCT03474315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multivariate assessment
Description: Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
Study NCT04455243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: 150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
Study NCT04455243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered in the same schedule and volume as NAC
Study NCT04095156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro assays.
Description: Biochemical and flow-cytometry analysis of specimen collected.
Study NCT00504556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban (DU-176b)
Description: 30mg tablet once daily
Study NCT00504556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban (DU-176b)
Description: 60mg tablet once daily
Study NCT00504556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban (DU-176b)
Description: 30mg tablet two times a day
Study NCT00504556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban (DU-176b)
Description: 60mg tablet two times a day
Study NCT00504556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: warfarin tablets
Study NCT01578564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR-C13
Description: Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
Study NCT02480985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pituitary function evaluation
Description: Pituitary function evaluation performed at hospital discharge, 6 and 12 months~* Thyroid-stimulating hormone, free T4 and T3~* Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone~* Adrenocorticotropic hormone stimulation test~* Glucagon test (growth hormone deficit)~Risk factors evaluation of pituitary dysfunction~* Demographic data~* Daily data (clinical exam, secondary brain injuries)~* Hormone levels on day 1, 3 and 7~* Biomarkers on day 1, 3 and 7~* Brain CT-Scan on day 1~* Pituitary MRI on day 7~Outcome measures at 6 and 12 months~* Neurological recovery (GOSe)~* Independent functioning (FIM)~* Quality of life (EQ-5D-5L)~* Life satisfaction (LISAT-11)~* Depression (PHQ-9)
Study NCT03810365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral treatment for insomnia
Description: Brief Behavioral Treatment for Insomnia includes content on sleep restriction, stimulus control, and sleep hygiene content with 1 month for primary outcome followed by 3 month 12 month follow-up visits.
Study NCT03810365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating Control
Description: Healthy eating control involves healthy eating content with 1 month for primary outcome followed by 3 month and 12 month follow-up visits.
Study NCT04402814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clungene rapid test cassette
Description: Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.
Study NCT01103115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium 600mg plus Vit D 400 IU
Description: Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
Study NCT01103115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium 600mg plus Vit D 800 IU
Description: Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
Study NCT01103115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copegus
Description: 1000 or 1200mg po daily for 24 or 48 weeks
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 or 1200mg po daily for 24 or 48 weeks
Study NCT03008408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT03008408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT03674840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angle kappa based SBL-3 implantation
Description: SBL-3 implantation based on kappa angle guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
Study NCT03674840 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 0 to 180 degree SBL-3 implantation
Description: SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegasys
Description: 180micrograms sc weekly for 24 or 48 weeks
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180micrograms sc weekly for 24 or 48 weeks
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po for 12 weeks
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po for 24 weeks
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591 (Danoprevir)
Description: 300mg po q8h for 12 weeks
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591 (Danoprevir)
Description: 600mg po q12h for 12 weeks
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591 (Danoprevir)
Description: 900mg po q12h for 12 weeks
Study NCT00963885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591 (Danoprevir)
Description: 300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
Study NCT03629002 — intervention group
Intervention type: BIOLOGICAL
Intervention: Study of the gene expression profile
Description: qPCR analysis
Study NCT02133677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 100mg
Description: WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
Study NCT03008408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT02310321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Once-daily oral administration on 14 consecutive days in every cycle in each period.
Study NCT02310321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.
Study NCT02310321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5.
Study NCT00339365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships Program
Description: Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
Study NCT00339365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Education Support Program
Description: EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
Study NCT04044794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
Study NCT03635866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluciclovine PET/MRI
Description: It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.
Study NCT03002857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA-C
Description: LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
Study NCT03002857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baska Mask
Description: Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
Study NCT03002857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel
Description: I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
Study NCT03024411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPod (Music/video games)
Description: Experimental patients will be given an iPod to enjoy music/video games during induction of labor.
Study NCT02672605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pennsylvania State Abortion Consent
Description: Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
Study NCT01314248 — intervention group
Intervention type: DEVICE
Intervention: each child will receive both the LMA and ILA
Description: each child will receive both the size 2 LMA and size 1.5 ILA
Study NCT00842465 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood collection for hormonal status analysis
Description: for hormonal status analysis
Study NCT00842465 — intervention group
Intervention type: PROCEDURE
Intervention: breast Biopsy or surgery
Description: breast Biopsy or surgery
Study NCT00842465 — intervention group
Intervention type: GENETIC
Intervention: blood collection
Description: blood collection for prlR gene sequencing
Study NCT00842465 — intervention group
Intervention type: OTHER
Intervention: ultrasonography (pelvis and breast), bone mineral density
Description: ultrasonography (pelvis and breast), bone mineral density
Study NCT01137565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
Study NCT01137565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to AMG 853
Study NCT01790308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: CSII for 2\~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
Study NCT01278641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded strength resistance training program
Description: Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
Study NCT01278641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Temperate pool exercise program
Description: Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
Study NCT01931449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified method of digestive tract reconstruction
Study NCT01931449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine digestive tract reconstruction
Study NCT04385251 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 \& 28:~Vital and hospitalization status; Symptoms and health status
Study NCT01897064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
Study NCT01897064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Psychiatric Treatment
Description: Standard psychiatric treatment.
Study NCT00526136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00526136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant (oral)
Description: Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
Study NCT02146690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: osteopathic manipulative treatment
Study NCT02146690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sham therapy
Study NCT02146690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Study NCT01285505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam commercial sublingual formulation
Description: 0.5 mg tablet, single dose
Study NCT01285505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam test sublingual tablet
Description: 0.5 mg tablet, single dose
Study NCT01875055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS and Algorithm
Description: NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
Study NCT01875055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS derived cerebral oximetry
Description: NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
Study NCT01875055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS derived cerebral oximetry
Description: NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers